INTRODUCTION

Cost-effectiveness of empagliflozin/linagliptin as 2nd-line therapy for adults with type 2 diabetes
Laura E. Henkhaus, BS † and Joel W. Hay, PhD; University of Southern California; Los Angeles, CA
• Considering the large and growing population with type 2 diabetes (T2D), 1 it is especially important to understand how to obtain the most value out of healthcare resources • Many T2D patients fail to control glucose levels with metformin alone, an oral treatment recommended for 1 stline therapy by the American Diabetes Association (ADA) 2 • Among oral antidiabetic drugs (OADs) recommended for dual therapy, DPP-4 and SGLT2 inhibitors are best tolerated but have lower levels of efficacy and are more expensive 2 (see Table 1 ) • In January 2015, the US Food and Drug Administration (FDA) approved the first combination therapy of SGLT2 and DPP-4 inhibitors, empagliflozin/linagliptin, and this oral combination pill went on US markets in March 2015 3 • In the randomized clinical trial (RCT) of patients inadequately controlled with metformin (NCT01422876) 4 :
• Patients in both combination groups achieved significantly greater mean reductions in glycated hemoglobin (HbA1c) compared to that of the single drug groups 4 (see Table 2 ) • All treatment regimens were well tolerated and similar in safely profile To evaluate the lifetime cost-effectiveness of empagliflozin/linagliptin combinations when compared to components for treatment of T2D in adults inadequately controlled with metformin, using a US societal perspective
OBJECTIVE
• Combination therapies were cost-effective compared to each singleingredient drug (see Table 4 ) • EL25 dominated EL10, costing slightly less (-$120) and providing 0.04 more QALYs • Net monetary benefit (NMB) was highest for linagliptin up to a willingness-to-pay (WTP) of $33,494; E25 then had highest NMB up to WTP of $119,224, above which EL25 had highest NMB • Results were robust to variations in costs of T2D and complications, utilities, and smoking behavior but sensitive to age, sex, and race • For 30-year-olds, combination therapies were no longer cost-effective compared to any single-ingredient component • For females and Blacks, combination therapies were no longer costeffective compared to empagliflozin • This study is the first-to the authors' knowledge-to evaluate the costeffectiveness of the empagliflozin/linagliptin combination • Empagliflozin/linagliptin combinations were cost-effective compared to single-ingredient components over a lifetime horizon for the studied cohort, but results differed for other populations • While empagliflozin/linagliptin is the only SGLT2 and DPP-4 combination pill currently on market, other combinations are in development 15 
Limitations
• Simulation of health outcomes relies on UKPDS equations, which do not exhaustively model all diabetes-related complications, e.g., neuropathy • Model relied on data from a 1-year RCT to simulate health outcomes for 40 years, thus if longer follow-up data reveals serious safety concerns, total benefits calculated in the present study would be overestimates 
